Draft

244  Ph Journal Club Sept 2022

244.1 Summary

  • Released Aug 26, 2022
  • 2019: 6th World Symposium update to mPAP 20mHg
  • Diagnosis
  • Screening: SSc, PoPH prior to transplant. Not in PE
  • Risk stratification and Monitoring
  • PAH medications
  • ICU Management, Transplan t
  • Congenital Heart disease
  • Group 2 IpcPH: PVR<2WU, CpcPH: PVR>2WU
  • Group 3: Severe (PVR >5 WU), non-severe PH (PVR ≤5 WU)
  • CTEPD (+/- PH)

244.2 Slide outline

244.2.1 Slide 1

  • Released Aug 26, 2022
  • Brian Locke, MD ### Slide 2
  • 2019: 6th World Symposium update to mPAP 20mHg
  • Treatment for mPAP 20-25, WU 2-3?
  • Exercise PH:
  • Normal range for mPAP/CO slope: 1.6 – 3.3 mmHg/L/min supine, age dependent (?60+)
  • Unclassified PH ### Slide 3
  • TODO: No text extracted from this slide. ### Slide 4
  • Diagnosis ### Slide 5
  • Screening: SSc, PoPH prior to transplant. Not in PE ### Slide 6
  • Risk stratification and Monitoring ### Slide 7
  • TODO: No text extracted from this slide. ### Slide 8
  • PAH medications ### Slide 9
  • ICU Management, Transplan t ### Slide 10
  • Congenital Heart disease ### Slide 11
  • Group 2 IpcPH: PVR<2WU, CpcPH: PVR>2WU ### Slide 12
  • Group 3: Severe (PVR >5 WU), non-severe PH (PVR ≤5 WU)
  • TTE less accurate
  • TRV unmeasurable >50%
  • Overestimates PAP
  • Severe PH indep of Spiro
  • Stronger assoc PaO2, DLCO, low CO2
  • ?OHS ### Slide 13
  • CTEPD (+/- PH) ### Slide 14
  • CTEPD (+/- PH) ### Slide 15
  • The End

244.3 Learning objectives

  • Released Aug 26, 2022
  • 2019: 6th World Symposium update to mPAP 20mHg
  • Diagnosis
  • Screening: SSc, PoPH prior to transplant. Not in PE
  • Risk stratification and Monitoring

244.4 Bottom line / summary

  • Released Aug 26, 2022
  • 2019: 6th World Symposium update to mPAP 20mHg
  • Diagnosis
  • Screening: SSc, PoPH prior to transplant. Not in PE
  • Risk stratification and Monitoring

244.5 Approach

  1. TODO: Outline the initial assessment or decision point.
  2. TODO: Outline the next diagnostic or management step.
  3. TODO: Outline follow-up or escalation criteria.

244.6 Red flags / when to escalate

  • TODO: List red flags that require urgent escalation.

244.7 Common pitfalls

  • TODO: Capture common errors or missed steps.

244.8 References

TODO: Add landmark references or guideline citations.

244.9 Slides and assets

244.10 Source materials